“With the significant changes at Nykode’s board level, and with the common understanding regarding the level of ambitions for our clinical oncology assets and the tolerance platform, we are exceptionally pleased to continue the important work at Nykode,” says Michael Engsig, CEO, Nykode.

The focus will now be on restoring the trust in Nykode among all of our important stakeholders, as well as creating value for our shareholders and other stakeholders.

“Further, I continue to have a very strong belief in Nykode, including the company’s technology platform, and our R&D pipeline. In addition, I continue to be impressed by the hard work most recently put in by our entire organization. The focus will now be on restoring the trust in Nykode among all of our important stakeholders, as well as creating value for our shareholders and other stakeholders, and I believe that we are in an excellent position to do so.”

Related article

Nykode Therapeutics’ Chair, Board Members, CEO, CSO and CFO to resign

Nykode Therapeutics has received notices of termination from Martin Nicklasson, Chair of the Board of Directors and Elaine Sullivan and Anne Whitaker, members of the Board of Directors. Further, Nykode has received notices of termination from Michael Engsig, Chief Executive Officer, Agnete Fredriksen, Chief Scientific Officer & Co-founder and Harald Gurvin, Chief Financial Officer.


“I am most pleased to continue at Nykode together with our incredible team of employees following the positive changes now taking place within the company,” says Agnete Fredriksen, CSO and co-founder of Nykode.

Related article

Agnete Fredriksen: “You really need to have drive to make it work”

Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula.


Board changes

The nomination committee has proposed Susanne Stuffers and Trygve Lauvdal as new members of the Board. In addition, Christian Åbyholm will continue as a member of the Board. It is the intention of the company to expand the Board with additional professional high-quality members, including a new Chair of the Board. The nomination committee has proposed that Susanne Stuffers is elected as Chair of the Board at the coming Extraordinary General Meeting. Harald Arnet has informed the nomination committee that he will step down from the Board. A vote will take place at the coming Extraordinary General Meeting on April 23, 2025.

Potential dividend

Certain major shareholders, Datum Group, RASMUSSENGRUPPEN AS and Victoria India Fund AS, have communicated to the company that they will propose to the new Board to put forward a proposal of a dividend of NOK 1.00 per share to the Annual General Meeting to be held on May 26, 2025.

Update on Nykode’s strategy

An updated company strategy will be presented in connection with the company’s second quarter 2025 results as part of Nykode’s objective of attracting additional international specialist investors and diversifying its shareholder base. This will include Nykode’s status, plans and strategy related to the company’s R&D pipeline, current trading and partner situation.